Product Approval / Regulatory Milestone
Marksans Pharma Receives USFDA Approval for Benzonatate Capsules
NSE
marksans
BSE
524404
Marksans Pharma Limited has received USFDA approval for Benzonatate Capsules (100 mg & 200 mg), strengthening its presence in the US generics market.
PRICE-SENSITIVE TRIGGER
Event: USFDA ANDA approval
Type: Product Approval / Regulatory Milestone
Impact: Positive
Immediate Effect: Expands US Portfolio and Revenue Potential
Key Details
- Product: Benzonatate Capsules USP (100 mg & 200 mg)
- Approval Type: ANDA (Abbreviated New Drug Application)
Regulator
USFDA
Reference Drug
Tessalon Capsules (Pfizer)
What Happened ?
Marksans Pharma has received final approval from the USFDA for its ANDA for Benzonatate Capsules.
The product is bioequivalent to the reference listed drug (Tessalon), used for treating cough-related conditions.
Strategic Impact & Details
- Strengthens US generics portfolio
- Adds new revenue stream
- Expands presence in respiratory segment
Insight: USFDA approvals are key growth drivers for pharma exporters
Management commentary
- Focus on expanding US product pipeline
- Strengthening generics portfolio
- Leveraging regulatory approvals for growth
Risk Analysis
Key Risks
- Pricing pressure in US generics market
- Competition from existing players
- Regulatory compliance risks
- Margin pressure
Worst Case Scenario
Low market share due to competition
Risk Level: Medium
Official Exchange Filing: Marksans Pharma Limited